Media stories about ENDRA Life Sciences (NASDAQ:NDRA) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ENDRA Life Sciences earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.2893453537115 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of ENDRA Life Sciences (NDRA) opened at 2.60 on Thursday. The stock’s market cap is $10.16 million. ENDRA Life Sciences has a 1-year low of $2.59 and a 1-year high of $4.00. The stock’s 50 day moving average price is $3.23 and its 200 day moving average price is $3.41.

ILLEGAL ACTIVITY NOTICE: “ENDRA Life Sciences (NDRA) Receiving Somewhat Favorable News Coverage, Study Shows” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/14/endra-life-sciences-ndra-receiving-somewhat-favorable-news-coverage-study-shows.html.

About ENDRA Life Sciences

ENDRA Life Sciences Inc develops photo- and thermo-acoustic medical technologies that bring new capabilities to existing ultrasound systems. Its photo-acoustic solutions help global medical researchers to screen and modify disease models with high image quality and volume scanning speed. The company offers the Nexus-128 system, a fully 3D imaging solution for imaging anatomy, physiology, and labeled molecular targets for institutions.

Receive News & Ratings for ENDRA Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.